GODAVARI DRUGS
|
|
BOM : 530317     NSE :      | |
LT :  
    Long Term Analysis
Fundamentals : Bad
Valuation : Good [Stock is Cheap] Debt : High |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Downward Pledged Shares : NA |
May 25,2022 |
Price(EOD): ₹ 67.60
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
MCap: ₹ 50.70 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
GODAVARI DRUGS | -1.4% | -5% | 15% |
SUN PHARMACEUTICAL INDUSTRIES | 3% | 1.3% | 31.9% |
DIVIS LABORATORIES | -16.2% | -20.1% | -9.3% |
DR REDDYS LABORATORIES | 9.6% | 4.7% | -16.9% |
CIPLA | 3.6% | 1.9% | 4.7% |
GLAND PHARMA | -11.4% | -16.5% | -9.6% |
PIRAMAL ENTERPRISES | -4.4% | -14.3% | 4.7% |
CADILA HEALTHCARE | 8.2% | 7.4% | -39.9% |
TORRENT PHARMACEUTICALS | 1.7% | -3.5% | -4.6% |
FUNDAMENTAL ANALYSIS OF GODAVARI DRUGS
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF GODAVARI DRUGS
 Ratio | Standalone | |
---|---|---|
P/E P/B P/S |
9.7
P/E Calculated based on EPS of 6.97
[ Mar2022 - Standalone Results ] 1.72
P/B Calculated based on Book Value of 39.35
[ Mar2022 - Standalone Results ] 0.31
P/S Calculated based on Revenues of 161.105 Cr
[ TTM - Standalone Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
113% -33% -26% |
SHARE PRICE MOMENTUM OF GODAVARI DRUGS
GODAVARI DRUGS vs SENSEX
DEBT OF GODAVARI DRUGS
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2022 2021 2020 Avg_3yrs |
0.78 1.25 1.36 1.13 |
- - - - |
[Last Annual Data : Mar2022]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF GODAVARI DRUGS
Pledged Promoter Shares |
NA | |
---|---|---|
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF GODAVARI DRUGS
Standalone | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
31.17% 4.6% 21.14% -4.88% |
34.35% 5.34% 19.2% -1.48% |
QtrlyTrend |
4 | |
Latest Qtr: Mar2022 | ||
Quarterly Result Analysis → |
GODAVARI DRUGS related INDICES
You may also like the below Video Courses
FAQ about GODAVARI DRUGS
Is GODAVARI DRUGS good for long term investment?
As on May 25,2022, the Fundamentals of GODAVARI DRUGS look Poor and hence it may not be good for long term investment ! See Financial Performance of GODAVARI DRUGS . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is GODAVARI DRUGS UnderValued or OverValued?
As on May 25,2022, GODAVARI DRUGS is Under Valued based on the estimates of intrinsic value and hence may be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of GODAVARI DRUGS ?
As on May 25,2022, the Intrinsic Value of GODAVARI DRUGS is Rs. 91.60 determined based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 31.68
Fair Value [Median EV / Sales Model] : Rs. 100.22
Fair Value [Median Price / Sales Model] : Rs. 91.60
Median Fair Value of GODAVARI DRUGS : Rs. 91.60
Is GODAVARI DRUGS trading at a Premium or Discount?
As on May 25,2022, GODAVARI DRUGS is trading at a Discount of -26% based on the estimates of Median Intrinsic Value!SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs DR REDDYS LABORATORIES LTD
CIPLA LTD vs GLAND PHARMA LTD vs PIRAMAL ENTERPRISES LTD
CADILA HEALTHCARE LTD vs TORRENT PHARMACEUTICALS LTD vs ALKEM LABORATORIES LTD
LUPIN LTD vs AUROBINDO PHARMA LTD vs BIOCON LTD
ABBOTT INDIA LTD vs LAURUS LABS LTD vs IPCA LABORATORIES LTD
